HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization
17 Octubre 2024 - 7:31AM
Business Wire
- Industry leader brings extensive experience in developing
go-to-market strategies for breakthrough products and delivering
growth
- Founder and current CEO Branislav Vajdic named President to
focus on advancing the Company’s groundbreaking vector-based
technology for heart health, including AI applications
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology
company focused on transforming cardiac care by providing powerful
insights wherever the patient is, announced that Robert Eno has
been appointed Chief Executive Officer (CEO), effective Monday,
October 21, 2024. The seasoned MedTech executive joined HeartBeam
as President in January 2023 and will lead as the Company continues
to work towards securing the foundational FDA 510(k) clearance for
its vector-based technology and prepares for commercialization and
growth.
As part of the long-planned transition, Branislav Vajdic, Ph.D.,
Founder and current CEO, will move into the role of President. In
this role, Dr. Vajdic will focus on further innovating on the
Company’s groundbreaking vector-based technology, driving research
and development efforts, and advancing artificial intelligence (AI)
applications.
“HeartBeam is at an important inflection point and the
transition comes at the right time where we can best leverage the
unique strengths of each leader. Branislav’s commitment to
innovation and vision of providing unprecedented cardiac insights
has enabled the Company to reach this pivotal point and we will
continue to benefit from his drive to unlock the transformative
opportunities ahead. Likewise, Rob has spent his career growing
companies with innovative technologies, based on his keen
understanding of sales, strategic marketing and go-to-market
strategies, while maximizing value for stakeholders, and I am
confident that his deep experience will ensure the Company is well
positioned for success,” said Rich Ferrari, Executive Chairman,
Board of Directors, HeartBeam.
HeartBeam’s core vector-based technology captures the heart’s
electrical signals from three dimensions to provide total heart
intelligence. The Company’s first application of the technology is
a cable-free, credit card-sized device that is designed to be
capable of synthesizing a 12-lead ECG. The HeartBeam system is
currently under review with the FDA. The Company has 13 issued U.S.
patents and 4 issued international patents supporting the
underlying technology.
“The HeartBeam technology is truly transformative and stands to
change how cardiac care is managed in the future. We’ve only
scratched the surface of unlocking new insights and understanding
how our data-rich signals can benefit physicians and patients,”
commented Mr. Eno. “I am honored to lead the Company at this
exciting time and look forward to my continued partnership with
Branislav as we evolve our business and technology to deliver on
strategic objectives.”
With over 30 years of experience, Mr. Eno, age 57, is a
passionate leader who has created go-to-market strategies for
multiple breakthrough products including noninvasive FFRCT for
diagnosing coronary artery disease, laser cataract surgery,
scanning retinal laser photocoagulation, and intravascular
brachytherapy. Before joining HeartBeam, Mr. Eno was Chief
Executive Officer of Preview Medical, a diagnostic equipment
company creating a new category of real-time, in vivo tissue
classification for solid tumor cancers, using machine learning and
proprietary optical signals. Previously, he was Senior Vice
President of Marketing for HeartFlow, leading all aspects of the
marketing and product functions for a new category of personalized,
noninvasive testing for heart disease, including its initial
product, HeartFlow FFRCT. He has also held senior marketing and
sales leadership roles at OptiMedica, NeoGuide Systems and Avantec
Vascular. Mr. Eno holds an MBA from the Stanford Graduate School of
Business and a BA, with Honors and Distinction, from Stanford
University, where he was Phi Beta Kappa.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company
dedicated to transforming cardiac care by providing powerful
cardiac insights wherever the patient is. The Company is creating
the first ever cable-free 12-lead ECG capable of capturing the
heart’s electrical signals from three dimensions. This platform
technology is designed to be used in portable devices that can be
used wherever the patient is to deliver actionable heart
intelligence. Physicians will be able to identify cardiac health
trends and acute conditions and direct patients to the appropriate
care – all outside of a medical facility, thus redefining the
future of cardiac health management. The Company holds 13 US and 4
international issued patents related to technology enablement.
For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our Forms 10-K, 10-Q and other reports filed with the SEC and
available at www.sec.gov. We urge you to consider those risks and
uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241017992227/en/
Investor Relations Contact: Chris Tyson Executive Vice
President MZ North America Direct: 949-491-8235 BEAT@mzgroup.us
www.mzgroup.us
Media Contact: media@heartbeam.com
HeartBeam (NASDAQ:BEAT)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
HeartBeam (NASDAQ:BEAT)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024